| Similar Articles |
|---|
 |
The Motley Fool
May 4, 2007
Mike Havrilla |
Taking It to the Affymax Positive clinical data for a potential anemia treatment has the drugmaker's stock on the rise.   |
The Motley Fool
August 9, 2010
Luke Timmerman |
Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug. |
The Motley Fool
October 7, 2010
Anders Bylund |
Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson. |
The Motley Fool
December 8, 2011
Luke Timmerman |
Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug Many investors wrote off Affymax in June 2010, but was that premature? |
The Motley Fool
December 5, 2011
Brian Orelli |
Up 20%, but Uncertainty Still Looms Affymax is still a risky bet. |
The Motley Fool
December 8, 2011
Brian Orelli |
A Soaring Biotech With Room to Run Affymax gets a leg up from an FDA advisory panel vote. |
Chemistry World
June 30, 2014
Phillip Broadwith |
Affymax folds after drug withdrawal Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anemia drug Omontys (peginesatide). |
The Motley Fool
October 30, 2010 |
Motley Fool Battle Royale Round 1: Goodyear vs. Affymax In this first-round stock matchup, the 100-year-old American superbrand Goodyear Tire & Rubber takes on Affymax. |
